[Drugs for Neglected Diseases initiative (DNDi)] Kinshasa / Paris / Geneva / Amsterdam -- · Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness